EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Type 1 Diabetes Risk Variants Reduce Beta Cell Function

Wiktoria Ratajczak, Angus G Jones, Sarah D Atkinson, Catriona Kelly

Genes · 2025

DOI: 10.3390/genes16020172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Wiktoria Ratajczak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Personalised Medicine Centre, School of Medicine, Ulster University, C-TRIC Building, Altnagelvin Hospital Campus, Glenshane Road, Derry BT48 7JL, UK. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Diabetes Mellitus, Type 1, Hepatocyte Nuclear Factor 1-alpha, Polymorphism, Single Nucleotide. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, Northern Ireland Public Health Agency (HSC R&D) & Ulst…, European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for Northern Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The variants rs10517086 and rs1534422 are predictive of type 1 diabetes mellitus (T1DM) development and poor residual β cell function within the first year of diagnosis. However, the mechanism by which risk is conferred is unknown. We explored the impact of both variants on β cell function in vitro and assessed their relationship with C-peptide in people with T1DM and type 2 diabetes mellitus (T2DM).

Methods

Using CRISPR/Cas9, the variants were introduced into a β cell line (BRIN-BD11) and a T cell line (Jurkat cells) from which the conditioned media was applied to otherwise healthy β cells to model the inflammatory environment associated with these variants.

Results

Both variants significantly reduced glucose-stimulated insulin secretion, increased production of pro-inflammatory cytokines and reduced expression of several β cell markers and transcription factors (KCNJ11, KCNQ1, SCL2A2, GCK, NKX6.1, Pdx1 NGN3). However, HNF1A was significantly upregulated in the presence of both variants. We subsequently silenced HNF1A in variant expressing BRIN-BD11 cells using siRNA and found that gene expression profiles were normalised. Induction of each variant significantly increased expression of the lncRNAs they encode, which was normalised upon HNF1A silencing. Analysis of the DARE (Diabetes Alliance for Research in England) study revealed an association of rs10517086_A genotype with C-peptide in 153 individuals with T1DM, but not in 417 people with T2DM.

Conclusions

These data suggest that rs1534422 and rs10517086 exert multiple insults on the β cell through excessive upregulation of HNF1A and induction of pro-inflammatory cytokines, and highlight their utility as prognostic markers of β cell function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Secreting CellsDiabetes Mellitus, Type 1Hepatocyte Nuclear Factor 1-alphaPolymorphism, Single NucleotideHumansDiabetes Mellitus, Type 2Insulin SecretionGenetic Predisposition to DiseaseCell LineMaleC-PeptideFemaleRNA, Long Noncoding

Stichwörter der Autor:innen

inflammationrisk variantstype 1 diabetesβ cells

Substanzen

Hepatocyte Nuclear Factor 1-alphaHNF1A protein, humanC-PeptideRNA, Long Noncoding

Autor:innen und Institutionen

  • Personalised Medicine Centre, School of Medicine, Ulster University, C-TRIC Building, Altnagelvin Hospital Campus, Glenshane Road, Derry BT48 7JL, UK.
  • University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter EX1 2LU, UK.
  • School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine BT52 1SA, UK.

Förderung

  • Wellcome Trust
  • European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, Northern Ireland Public Health Agency (HSC R&D) & Ulst…
  • European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for Northern Ireland
  • Northern Ireland Public Health Agency (HSC R&D)
  • Ulster University
  • Department for the Economy, Northern Ireland
  • Exeter NIHR Clinical Research Facility

Zitieren

APA

Ratajczak, W., Jones, A. G., Atkinson, S. D., & Kelly, C. (2025). Type 1 Diabetes Risk Variants Reduce Beta Cell Function. Genes. https://doi.org/10.3390/genes16020172

Vancouver

Ratajczak W, Jones AG, Atkinson SD, Kelly C. Type 1 Diabetes Risk Variants Reduce Beta Cell Function. Genes. 2025. doi:10.3390/genes16020172

BibTeX
@article{Ratajczak2025,
  author = {Ratajczak, Wiktoria and Jones, Angus G and Atkinson, Sarah D and Kelly, Catriona},
  title = {Type 1 Diabetes Risk Variants Reduce Beta Cell Function},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16020172}
}
Kostenlos starten →